• Participants were randomised to renal denervation or sham therapy, with no change to antihypertensive treatment within two months post-randomisation. (cardionewsuk.org)
  • One of the most important new treatment options is the percutaneous treatment for aortic valve stenosis (transcatheter aortic valve implantation), since aortic valve disease is a rather common problem in elderly patients, with many of them at high risk for surgery. (bmj.com)
  • Foremost in the development of percutaneous treatment options for aortic valve stenosis, transcatheter aortic valve implantation (TAVI) has improved the treatment options for elderly patients with aortic valve stenosis. (bmj.com)
  • First clinical results of transcatheter aortic valve implantation (TAVI) using the Jenavalve system (Jenavalve) in patients with severe aortic regurgitation show that the device is safe and efficient in high-risk patients, significantly improves New York Heart Association (NYHA) classification. (cardiovascularnews.com)
  • An economic analysis of data from the PARTNER 3 randomised trial, comparing transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR) in patients with severe aortic stenosis and low surgical risk, found that despite higher up-front procedural costs, at two-year follow-up, quality-adjusted life expectancy was greater and total costs were lower with TAVI. (cardiovascularnews.com)
  • Five-year clinical and echocardiographic outcome data from the SURTAVI randomised trial comparing transcatheter aortic valve implantation (TAVI) using an early-generation device to surgical aortic valve replacement (SAVR) have shown no difference in all-cause mortality or stroke between the two procedures in patients at intermediate surgical risk. (cardiovascularnews.com)
  • Two-year findings of a post-hoc study from the GALILEO trial, investigating the clinical outcomes after successful transcatheter aortic valve implantation with a balloon-expandable or a self-expanding valve, suggest that there are comparable outcomes between the two devices. (cardiovascularnews.com)
  • This year has seen a fundamental shift in the balance between transcatheter aortic valve implantation (TAVI) and aortic valve replacement surgery for the treatment of aortic stenosis. (icrjournal.com)
  • Other procedures discussed in this review are the percutaneous left atrial appendage closure as a non-pharmacologic therapy to prevent strokes, and renal denervation for resistant hypertension. (bmj.com)
  • Other important developments are the percutaneous treatment options for mitral regurgitation (MR) (MitraClip), non-pharmacologic therapy to prevent cerebral embolisation in patients with atrial fibrillation (AF) such as left atrial appendage (LAA) closure and closure of the patent foramen ovale, and renal denervation to treat resistant hypertension. (bmj.com)
  • He is also becoming increasingly involved in the percutaneous aortic valve programme at Harefield Hospital. (bupa.co.uk)
  • Percutaneous renal denervation: new treatment option for resistant hypertension and more? (bmj.com)
  • Dr. Arif Al Nooryani is an expert of interventional cardiology with a high level experience in coronary stents, peripheral arteries intervention and management of structural heart disease including TAVI, Aortic Valve implantation and mitral valve repair through catheterization. (gph.ae)
  • This has come about as a result of the publication of the Placement of Aortic Transcatheter Valves (PARTNER) 3 trial in 2019, followed shortly afterwards by Mick Jagger undergoing what looks to have been a successful and uncomplicated TAVI. (icrjournal.com)
  • He has been worked lately on invasive treatment methods of resistant hypertension by novel sympathetic denervation techniques of the renal arteries (chemical denervation, barodenervation). (wikipedia.org)
  • The trial, Symplicity HTN-2: International, Multicenter, Prospective, Randomized, Controlled Trial of Endovascular Selective Renal Sympathetic Denervation for the Treatment of Hypertension, compared 52 participants who were randomly assigned to catheter treatment plus medication to 54 controls who received medication alone. (blogspot.com)
  • He was also trained in carotid and peripheral artery stenting, left atrial appendage closure for stroke prevention and transcatheter aortic valve replacement (TAVR) for severe aortic valve stenosis. (gleneagles.com.sg)
  • Sleep apnea, chronic kidney disease, obesity, or renal artery stenosis are other causes of secondary hypertension. (msdmanuals.com)
  • This new edition is devoted to a broad array of topics involving the circadian variation in cardiovascular diseases, with focuses on hypertension, stroke, and coronary disease. (nshealth.ca)
  • The first is related to an insult caused directly to autonomic nerves, whereas the other can be secondary to cardiovascular dysfunction, such as dilated cardiomyopathy and aortic stiffness. (encyclopedia.pub)
  • OSA is a risk factor for cardiovascular disorders including hypertension, congestive heart failure (CHF), myocardial ischemia, arrhythmias and infarction, and cerebrovascular conditions including stroke [ 3 ]. (hindawi.com)
  • This book guides readers through the correct use and consequent diagnostic and therapeutic relevance of 24-h ambulatory blood pressure monitoring (ABPM) in a wide spectrum of clinical presentations and different phenotypes of arterial hypertension. (nshealth.ca)
  • A study o aortic dissection rupture, abdominal wall and coagulation disturbances vascular factors tenuous, involuting capillaries with large arterial or venous pressure, it should be informed about the need for anticoagulation, especially in patients with cidp. (easternpropane.com)
  • However, the intact EGL could protect the arterial wall from hypertension so that the LDL concentration in the intima layer was almost the same as that under normal pressure conditions. (nartsignaling.com)
  • In conclusion, an intact EGL with a sufficient thickness may act as a barrier to LDL infiltration into the arterial wall and has the potential to suppress the hypertension-driven hike of LDL infiltration/accumulation in the arterial wall. (nartsignaling.com)
  • Six-month outcomes from the randomised RADIANCE-HTN TRIO trial, comparing endovascular ultrasound renal denervation to a sham procedure for treatment-resistant hypertension, demonstrate the additional effects of pharmacologic intervention with maintenance of a blood pressure-lowering effect of renal denervation at six months, according to investigators. (cardiovascularnews.com)
  • Background: The RADIANCE-HTN SOLO, RADIANCE-HTN TRIO, and RADIANCE II randomized, sham-controlled trials independently met their primary endpoint of a greater reduction in daytime ambulatory systolic blood pressure (SBP) at 2 months after ultrasound renal denervation (uRDN) in patients with hypertension. (bvsalud.org)
  • Importance: Two initial sham-controlled trials demonstrated that ultrasound renal denervation decreases blood pressure (BP) in patients with mild to moderate hypertension and hypertension that is resistant to treatment. (bvsalud.org)
  • Objective: To study the efficacy and safety of ultrasound renal denervation without the confounding influence of antihypertensive medications in patients with hypertension. (bvsalud.org)
  • Patients with an estimated glomerular filtration rate of 40 mL/min/1.73 m2 or greater and with suitable renal artery anatomy were randomized 2:1 to undergo ultrasound renal denervation or a sham procedure. (bvsalud.org)
  • Interventions: Ultrasound renal denervation vs a sham procedure. (bvsalud.org)
  • Among 7 secondary BP outcomes, 6 were significantly improved with ultrasound renal denervation vs the sham procedure. (bvsalud.org)
  • Conclusions and Relevance: In patients with hypertension, ultrasound renal denervation reduced daytime ambulatory SBP at 2 months in the absence of antihypertensive medications vs a sham procedure without postprocedural major adverse events. (bvsalud.org)
  • Importance: Ultrasound renal denervation (uRDN) was shown to lower blood pressure (BP) in patients with uncontrolled hypertension (HTN). (bvsalud.org)
  • Some of his main research interests include coronary heart disease, detection and treatment of vulnerable atheromatic plaque, aortic elastic properties, mitral valve disease, interventional treatment of resistant hypertension and designing many catheter types used for various diagnostic and therapeutic interventional procedures. (wikipedia.org)
  • Hypertension is defined as a systolic blood pressure (SBP) of 140 mm Hg or more, or a diastolic blood pressure (DBP) of 90 mm Hg or more, or taking antihypertensive medication. (medscape.com)
  • Patients aged 18 years to 75 years with hypertension (seated office systolic BP [SBP] ≥140 mm Hg and diastolic BP [DBP] ≥90 mm Hg despite taking up to 2 antihypertensive medications) were eligible if they had an ambulatory SBP/DBP of 135/85 mm Hg or greater and an SBP/DBP less than 170/105 mm Hg after a 4-week washout of their medications. (bvsalud.org)
  • Interventional cardiology is no longer limited to the treatment of coronary artery disease but allows also treatment of valvular disease, stroke prevention, hypertension, etc. (bmj.com)
  • 1) Patients with severe resistant hypertension were randomly assigned in a 2:1 ratio to undergo renal denervation or a sham procedure. (amegroups.org)
  • In the industry-funded SYMPLICITY HTN-3 trial, patients with resistant hypertension (≥160 mm Hg) were randomly assigned to undergo renal-artery denervation or only renal angiography (sham control), but the participants were unaware of their randomized assignment. (jwatch.org)
  • Would you advise any patients with hypertension to undergo renal denervation? (jwatch.org)
  • Perioperative and long-term outcomes after open conversion of endovascular aneurysm repair versus primary open aortic repair. (sc-ctsi.org)
  • He has also successfully treated many patients with resistant hypertension via noninvasive renal denervation device therapy. (gleneagles.com.sg)
  • The authors summarize that this blinded trial did not show a significant reduction of systolic blood pressure in patients with resistant hypertension 6 months after renal-artery denervation as compared with a sham control. (amegroups.org)
  • Patients may have undiagnosed hypertension for years without having had their BP checked. (medscape.com)
  • There is a significant association between the blood pressure and insulin sensitivity about 60 - 80 % of the patients with diabetes Hypertension. (scitcentral.com)
  • A procedure to deactivate nerves around the kidney arteries substantially reduces blood pressure in patients whose hypertension is not adequately reduced by medications, according to a new study. (blogspot.com)
  • The treatment shows promise for hypertensive patients whose high blood pressure isn't lowered enough by currently available treatments, which is the case for about one in five people with hypertension. (blogspot.com)
  • CHICAGO, Nov. 17, 2010 - A non-drug treatment that silences nerves near the kidneys safely and significantly reduced blood pressure in patients unable to control their hypertension despite taking an average of five medications, according to late breaking clinical trial research presented at the American Heart Association's Scientific Sessions 2010. (blogspot.com)
  • Resistant hypertension is common, occurring in perhaps 15 percent to 20 percent of patients. (blogspot.com)
  • Target blood pressure is usually unattainable with drug therapy in patients with severely resistant hypertension," Esler said. (blogspot.com)
  • Certain pathogenic organisms such as MRSA, Clostridium difficile, and Vancomycin-resistant enterococci can be transmitted directly through contact with infected or colonized patients, or indirectly through contact with potentially contaminated items or surfaces. (biomedfrontiers.org)
  • On the basis of eight case studies, the author reviews and discusses current guidelines and recommendations aimed at optimizing the diagnostic and therapeutic approach in commonly encountered real-world clinical scenarios, including challenging cases of white-coat hypertension, masked hypertension, isolated nocturnal or diurnal hypertension, hypertension and obstructive sleep apnea, pseudo-resistant and true-resistant hypertension, and drug-induced hypotension. (nshealth.ca)
  • Clinical case 1: Patient with white-coat hypertension -- Clinical case 2: Patient with masked hypertension -- Clinical case 3: Patient with isolated diurnal hypertension -- Clinical case 4: Patient with isolated nocturnal hypertension -- Clinical case 5: Patient with hypertension and OSA -- Clinical case 6: Patient with resistant hypertension -- Clinical case 7: Patient with pseudo-resistant hypertension -- Clinical case 8: Patient with drug-induced hypotension. (nshealth.ca)
  • Other studies may be obtained on the basis of clinical findings or in individuals with suspected secondary hypertension and/or evidence of target-organ disease, such as CBC, chest radiograph, uric acid, and urine microalbumin. (medscape.com)
  • Other methods to control and monitor blood pressure to manage renoprotection are under clinical investigation, which includes renal denervation, and endothelin receptor antagonism. (scitcentral.com)
  • Hypertension may be primary, which may develop as a result of environmental or genetic causes, or secondary, which has multiple etiologies, including renal, vascular, and endocrine causes. (medscape.com)
  • Primary or essential hypertension accounts for 90-95% of adult cases, and secondary hypertension accounts for 2-10% of cases. (medscape.com)
  • The historical and physical findings that suggest the possibility of secondary hypertension are a history of known renal disease, abdominal masses, anemia, and urochrome pigmentation. (medscape.com)
  • Hypertension with an identified cause (secondary hypertension) is usually due to primary aldosteronism. (msdmanuals.com)
  • Comparative outcomes of physician-modified fenestrated-branched endovascular repair of post-dissection and degenerative complex abdominal or thoracoabdominal aortic aneurysms. (sc-ctsi.org)
  • 1) elevated BP, with a systolic pressure (SBP) between 120 and 129 mm Hg and diastolic pressure (DBP) less than 80 mm Hg, and (2) stage 1 hypertension, with an SBP of 130 to 139 mm Hg or a DBP of 80 to 89 mm Hg. (medscape.com)
  • Selection criterion for endovascular aortic repair in those with chronic kidney disease. (sc-ctsi.org)
  • Risk of Stroke with Thoracic Endovascular Aortic Repair of the Aortic Arch. (sc-ctsi.org)
  • Negative Findings on Renal Denervation for Hypertension: Sweet SYMPLICITY? (jwatch.org)
  • What do you consider the most likely explanation for the discrepancy between the findings from SYMPLICITY HTN-3 and those from previous studies of renal denervation? (jwatch.org)
  • thus, clinicians may consider other medications with anticholinergic side e ect o potentially toxic doses are correct according to symptoms of bleeding or lack of administration of broad spectrum antibiotics, including erythromycin and infantile scoliosis in which the patient have resistant hypertension and contributing to anemia of chronic gvhd is multifaceted, involving almost any organ system, the vestibular ocular re ex, and gaithexaminations are normal. (easternpropane.com)
  • Most groups, including the JNC, the American Diabetes Associate (ADA), and the American Heart Association/American Stroke Association (AHA/ASA) recommend lifestyle modification as the first step in managing hypertension. (medscape.com)